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Mean Centering Method for determination of Empagliflozin and
Metformin
Bassam M Ayoub, Rola M Emam, Mahmoud M Youssef, Muhammad N El-Kattan, Marwa A Sayed, Ahmed M Kowider,
Adly H Seha, Engy A Rabea, Rana M Yakout, Rolly H Faried
ABSTRACT
Introduction of computer-assisted analysis to pharmaceutical
products is considered a significant approach. A new method
was developed for simultaneous determination of empagliflozin
and metformin manipulating their ratio spectra with
application on recently approved pharmaceutical combination,
Synjardy® tablets. Spiking technique was used to increase the
concentration of empagliflozin after extraction from tablets
to allow its simultaneous determination with metformin
without prior separation. Validation parameters according to

ICH guidelines were acceptable over the concentration range
of 2-12 μg/mL for both drugs. Mean centering was performed
using Minitab® program. Using computer assisted programs
after spiking accompanied with direct UV measurement of
the drugs was satisfactory for accurate assay without complex
instrumentations. The optimized method was proved to be
suitable for industrial QC labs.
Keywords: Spiking; Chemometry; Computer-assisted analysis;
Mean Centering; Empagliflozin; Metformin.
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Synjardy® is composed of empagliflozin from the gliflozin
class that was recently approved for the treatment of type
2 diabetes as a sodium glucose co-transporter 2 inhibitor
enhancing urinary glucose excretion [1] and metformin
which is the drug of choice in mixed therapy for type 2
diabetes. Only one chromatographic method [2] and one
spectrophotometric method [3] were developed for its
pharmaceutical analysis. The aim of the present work is to
present a new simple computer-assisted mean centering
method [4] for the analysis of empagliflozin and metformin
taking in consideration the spiking criteria. Spiking technique
was used to increase the concentration of empagliflozin after
extraction from tablets allowing its determination despite its
low contribution.
Spectrophotometric assays for some recently approved antidiabetic drugs (Table 1) showed more facilitated, simple
and cost effective methods [5-11]. Furthermore, it showed
the advantages of low cost solvents, shorter analysis time
and simple instrumentation instead of complex details
implemented in the chromatographic method development.
Spectrophotometric analysis exhibited more economic and
simple assays [5-11] either using direct UV determination or
669
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Table 1. Spectrophotometric methods for analysis of some recently approved anti-diabetic drugs in pharmaceutical
formulations namely linagliptin and alogliptin.
Method

Detection wavelength

Linearity (µg/mL)

Direct UV

277 nm

2-6

Assay of linagliptin in Glyxambi® tablet (5)

Direct UV

294 nm

5-25

Assay of linagliptin in Tradjenta® tablets (6)

Direct UV

241 nm

10-35

Assay of linagliptin in Tradjenta® tablets (7)

Direct UV

276 nm

5-35

Assay of alogliptin in Nesina® tablets (8)

Simultaneous equation

224 nm

0.5-18

Assay of alogliptin in Kazano® tablets (9)

Absorption ratio

251 nm

0.5-18

Assay of alogliptin in Kazano® tablets (9)

First derivative

222 nm

2-16

Assay of alogliptin in Nesina® tablets (10)

by manipulation of the obtained spectra with acceptable limit
of detection (LOD) and limit of quantification (LOQ) values
that ensured satisfying sensitivity. Mostly used solvents were
distilled/deionized water and methanol. The applications of
cost effective spectrophotometric methods have renovated
the concept of analysis in a highly accurate and precise way.

2. Experimental
2.1. Instrumentation
JASCO double-beam UV spectrophotometer (S/N
C367961148, Japan) supported with Spectra Manager®
software were used.
®

2.2. Reagents, reference standard samples and working
solutions
Empagliflozin certified to contain 99.70 %, metformin
certified to contain 99.80 % and Synjardy® tablets
nominally containing 12.5 mg of empagliflozin and 500
mg of metformin per tablet were supplied from Boehringer
Ingelheim (Germany). Working solutions (20 µg/mL) were
prepared in methanol.
2.3. Sample preparation
The coats of ten Synjardy® tablets were carefully removed and
then the tablets were powdered and mixed. An accurately
weighed amount equivalent to 2.5 mg of empagliflozin and
100 mg of metformin was made up to 100 mL with methanol,
sonicated to dissolve and filtered. One mL of the extract was
transferred to a 100 mL volumetric flask, spiked with 10 mL
of empagliflozin working solution and finally completed to
volume with methanol.

Application

2.4. Procedure
2.4.1. Preliminary investigation
Zero-order absorption spectra of empagliflozin (8 µg/mL)
and metformin (8 µg/mL) were recorded separately against
methanol as a blank showing the maximum absorption (λmax)
at 225 nm and 237 nm, respectively (Figure 1).
2.4.2. Linearity
Accurately measured aliquots of working solutions equivalent
to 20-120 µg of each drug were transferred separately into a
series of 10 mL volumetric flasks, completed to volume with
methanol. The previously scanned spectra of empagliflozin
and metformin were divided separately by (10 µg/mL of
metformin) and (12 µg/mL of empagliflozin, respectively.
The obtained ratio spectra were mean centered and then the
mean centered values of empagliflozin and metformin were
measured at 221.8 nm and 249.2 nm, respectively. Calibration
curves were attained by plotting the mean centered values
against concentration.
2.4.3. Assay of laboratory prepared mixtures
Three different ratios (1:3, 1:1 and 3:1) of the laboratory
prepared mixtures were prepared using concentrations
equivalent to (3, 6, 9 µg/mL) and (9, 6, 3 µg/mL) of
empagliflozin and metformin, respectively. The zero order
spectra of each mixture were recorded using methanol as
blank. Then obtained spectra were divided by (10 µg/mL
of metformin) and (12 µg/mL of empagliflozin) separately
in order to get the ratio spectra that will be manipulated by
the mean centering method to calculate the corresponding
concentration of each drug. The ratio spectra divided by
metformin were mean centered using Minitab® program.
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Figure 1. Overlay of the absorption spectra of EG (8 µg/mL) and MT (8 µg/mL), using methanol as a blank.

The mean centered values were measured at 221.8 nm for
empagliflozin determination, while the mean centered values
of the ratio spectra divided by empagliflozin were used for
determination of metformin by measuring the mean centered
values at 249.2 nm.
2.4.4. Accuracy, repeatability and intermediate precision
The laboratory prepared mixtures prepared under 2.4.3 were
analyzed using the proposed method three times within the
same day and on three successive days. The mean of the
percent recoveries (R %) and the percent relative standard
deviation (RSD %) were then calculated for each method.
2.4.5. Assay of Synjardy® tablets
The absorbance spectrum of the tablet extract prepared
under section 2.3 was recorded using methanol as blank. The
obtained spectra were divided by (10 µg/mL metformin) and
(12 µg/mL empagliflozin) separately in order to record the
ratio spectra that will be manipulated by the mean centering
method to calculate the corresponding concentration of each
drug as discussed under (section 2.4.3).

2.4.6. Forced degradation of empagliflozin
Forced degradation study of empagliflozin, as a recently
approved drug, included solid state (thermal and photodegradation) and solution state (acid, alkali and H2O2) stress
conditions were performed. To a series of test tubes, each one
contains 2.5 mL of working solution, 2.5 mL of 0.3% H2O2, 1N
NaOH and 1N HCl were added separately and heated at 60 ◦C
for 0.5 h, then the acid and alkali mixtures were neutralized
and each mixture was completed to 10 mL with methanol.
The dry powder of empagliflozin was placed in oven at 55 ◦C
for 6 h & placed under UV lamp for 6 h and then dissolved in
methanol to give a proposed concentration of 5 µg/mL.

3. Results and discussion
The absorption spectra of each drug were divided by the
spectrum of a selected divisor (the other drug) to get the
ratio spectra, then mean centering method [4] was applicable
as empagliflozin and metformin are non-interactive drugs
and each of them obey Beer’s law according to the following
equation (Va = AEG CEG + AMT CMT). Where, Va is the vector of
absorbance, (AEG - AMT) are the molar absorptivities, (CEG CMT) are the concentrations of empagliflozin and metformin,
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respectively. After division over AMT, the produced ratio
spectra will be mean centered; CMT will be zero value
enabling the determination of CEG without interference from
metformin and the same concept regarding AEG.
The obtained absorption spectra of both empagliflozin
and metformin were divided by the spectrum of 10 μg/mL
metformin and 12 μg/mL empagliflozin, respectively and
then mean centered using Minitab® program (Figure 2).
Empagliflozin and metformin were determined at 221.8 nm
and 249.2 nm, respectively in a concentration range of 2-12
μg/mL.
All the validation parameters were found to be compatible
with ICH guidelines [12]. The validity of the calibration
curves over the concentration range (2-12 μg/mL) was
validated by the obtained low values of LOD - LOQ
parameters, and acceptable values of STEYX, Sb & Sa as
shown in (Table 2). Where; LOD is the limit of detection
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which represents drug concentration at STEYX/S ratio of 3.3,
LOQ is the limit of quantification at which STEYX/S is 10,
STEYX is the residual standard deviation of the regression
line, Sb is the standard deviation of the slope and Sa is the
standard deviation of the intercept. Also the developed
method was adopted successfully for determination of the
investigated drugs in laboratory prepared mixtures (Figure
2).
Influence of different variables was studied, including
scanning speed, wavelength of measurements, divisor
concentration and smoothing factor. Different concentrations
of both drugs (6, 8, 10, 12, 14 and 16 μg/mL) were tried as
divisors. Concentration of 12 μg/mL empagliflozin and 10
μg/mL metformin were selected as the best divisors with
minimum noise. No significant difference was found using
different smoothing factors, so it was excluded from the
method.

Figure 2. The mean centered values of the ratio spectra representing (2-12 μg/mL) EG divided by 10 μg/mL MT (a), the ratio
spectra of (2-12 μg/mL) MT divided by 12 μg/mL EG (b) and the ratio spectra of the laboratory prepared mixtures divided
separately by 10 μg/mL MT (c), and 12 μg/mL EG (d).
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Table 2. Results obtained by the proposed mean centering method
Item
Wavelength of measurements
Linearity range
Regression equation
Correlation coefficient (r)
Sb
Sa
C.I. of the slope
C.I. of the intercept
STEYX
LOD (μg/mL)

Empagliflozin
221.8 nm
2-12 μg/mL
Mv = 0.0404 Cμg/mL + 0.0024
0.9998
1.7 x 10-4
1.6 x 10-3
0.0404 ± 7 x 10-6
0.0024 ± 3.97 x 10-6
0.0014
0.11

Metformin
249.2 nm
2-12 μg/mL
Mv = 0.9338 Cμg/mL + 0.0391
0.9999
0.004
0.04
0.9338 ± 3.8 x 10-3
0.0391 ± 1.5 x 10-3
0.034
0.12

LOQ (μg/mL)

0.34

0.36

Accuracy (Mean ± SD)

99.88 % ± 0.62

100.09 % ± 0.55

Intraday RSD %

0.17-0.22

0.10-0.23

Interday RSD %

0.13-0.18

0.12-0.27

Drug in dosage form (Mean ± SD)

96.44 % ± 0.35

99.96 % ± 0.32

Where Mv is the mean centered value, C is the concentration
of the drug, Sb is the standard error of slope, Sa is the standard
error of intercept, C.I. is the confidence interval, STEYX is
the residual standard deviation of the regression line, LOD
is the limit of detection, LOQ is the limit of quantification,
SD is the standard deviation, RSD % is the percent relative
standard deviation.
Accuracy of the results was checked by calculating the
percent recovery of different concentrations of each
drug in laboratory prepared mixtures. The mean of the
recovery and standard deviations were shown in (Table 2).
Precision of the methods was checked using intraday and
interday records of the same laboratory prepared mixtures.
The RSD % of recoveries was calculated and found to be
less than 1%.
To check the specificity of the method, each drug was
determined in laboratory prepared mixture and in Synjardy®
tablets in the presence of excipients including copovidone,
corn starch, colloidal silicon dioxide, magnesium stearate,
hypromellose, titanium dioxide, talc, polyethylene glycol 400
and ferric oxide. And the results are shown in (Table 2). The
forced degradation study showed 24 % degradation in case of
alkaline stress conditions, 5 % in case of acidic degradation
and no degradation behavior was observed under the applied
oxidative, thermal and photo-degradation conditions as a
required specificity for the validated procedure. Statististical
analysis (Table 3) showed no significant difference in
comparison to a spectrophotometric method [3] at P>0.05,

with F = 0.001, P = 0.977 for empagliflozin and F = 0.335, P
= 0.594 for metformin.
Table 3. One way ANOVA results at P<0.05 for the proposed
method for determination of empagliflozin and metformin
against reference method [3].
Groups
*Reference method [3]
*Proposed method

Empagliflozin
Mean
S.D.
99.86
0.95
99.88
0.62

Metformin
Mean
S.D.
100.48
1.03
100.09
0.55

*Studied groups showed no significant difference at P>0.05, with
F = 0.001, P = 0.977 for empagliflozin and F = 0.335, P = 0.594 for
metformin.
Abbreviations: S.D. = standard deviation

4. Conclusion
The proposed analytical method proved to be accurate
for determination of empagliflozin and metformin as an
economic assay based on simple instruments and computer
assisted programs. The methods were applied successfully on
the pharmaceutical dosage form with acceptable validation
results. Spiking technique was crucial in the developed
method which allowed the direct measurement of the minor
component in the mixture. The developed method should
be of interest to the analysts in the area of drug control and
can be used by QC laboratories for the analysis of recently
approved Synjardy® tablets.
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